<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00709371</url>
  </required_header>
  <id_info>
    <org_study_id>ZB-202</org_study_id>
    <nct_id>NCT00709371</nct_id>
  </id_info>
  <brief_title>Zonisamide SR Plus Bupropion SR Combination Therapy in Subjects With Obesity</brief_title>
  <official_title>A Phase IIB, Multi-Center, Dose-Parallel, Randomized, Double-Blind, Monotherapy and Placebo-Controlled Safety and Efficacy Study of Zonisamide SR Plus Bupropion SR Combination Therapy in Subjects With Obesity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Orexigen Therapeutics, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Orexigen Therapeutics, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is determine if the combination of zonisamide SR and bupropion SR
      are is more effective than either drug given alone or placebo in the treatment of obesity.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage change in total body weight</measure>
    <time_frame>from baseline to 24 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">729</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Combination tablet containing Zonisamide SR placebo plus bupropion SR placebo SR = Sustained Release</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bupropion 360</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Combination tablet containing Zonisamide SR placebo plus bupropion SR 360 mg/day; SR = Sustained Release</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Zonisamide 120</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Combination tablet containing Zonisamide SR 120 mg/day plus bupropion SR placebo; SR = Sustained Release</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Zonisamide 360</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Combination tablet containing Zonisamide SR 360 mg/day plus bupropion SR placebo; SR = Sustained Release</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Zonisamide 120/Bupropion 360</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination tablet containing Zonisamide SR 120 mg/day plus bupropion SR 360 mg/day; SR = Sustained Release</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Zonisamide 360/Bupropion 360</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination tablet containing Zonisamide SR 360 mg/day plus bupropion SR 360 mg/day; SR = Sustained Release</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zonisamide SR placebo/ bupropion SR placebo</intervention_name>
    <description>2 placebo combination tablets twice daily for 16 weeks (maintenance period)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zonisamide SR placebo/ bupropion SR 360 mg/day</intervention_name>
    <description>2 placebo and bupropion SR 90 mg combination tablets, twice daily for 16 weeks (maintenance period)</description>
    <arm_group_label>Bupropion 360</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zonisamide SR 120 mg/day/ bupropion SR placebo</intervention_name>
    <description>2 zonisamide SR 30 mg and placebo combination tablets, twice daily for 16 weeks (maintenance period)</description>
    <arm_group_label>Zonisamide 120</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zonisamide SR 360 mg/day/ bupropion SR placebo</intervention_name>
    <description>2 zonisamide SR 90 mg and placebo combination tablets, twice daily for 16 weeks (maintenance period)</description>
    <arm_group_label>Zonisamide 360</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zonisamide SR 120 mg/day/ bupropion SR 360 mg/day</intervention_name>
    <description>2 zonisamide SR 30 mg and bupropion SR 90 mg combination tablets, twice daily for 16 weeks (maintenance period)</description>
    <arm_group_label>Zonisamide 120/Bupropion 360</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zonisamide SR 360 mg/day/ bupropion SR 360 mg/day</intervention_name>
    <description>2 zonisamide SR 90 mg and bupropion SR 90 mg combination tablets, twice daily for 16 weeks (maintenance period)</description>
    <arm_group_label>Zonisamide 360/Bupropion 360</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female or male subjects, 18 to 65 years of age

          -  Have body mass index (BMI) ≥ 30 kg/m2 and ≤ 45 kg/m2 for subjects with uncomplicated
             obesity, and BMI of ≥ 27 kg/m2 and ≤ 45 kg/m2 for subjects with obesity and
             dyslipidemia and/or controlled hypertension

          -  Non-smoker and no use of tobacco or nicotine products for at least 6 months prior to
             screening

          -  Normotensive (systolic ≤140 mm Hg; diastolic ≤90 mm Hg). Anti-hypertensive medications
             are allowed with the exception of adrenergic blockers and clonidine. Medical regimen
             must be stable for at least 6 weeks prior to randomization

          -  Triglycerides &lt;400 mg/dL. Medications for treatment of dyslipidemia are allowed with
             the exception of cholestyramine and cholestypol as long as medical regimen has been
             stable for at least 6 weeks prior to randomization

          -  No clinically significant laboratory abnormalities

          -  Negative urine drug screen

          -  Negative serum pregnancy test in women of child-bearing potential

          -  Women of child-bearing potential must be non-lactating, and agree to use acceptable
             contraception throughout the study period and for 30 days after discontinuation of
             study drug

          -  Able to comply with all required study procedures and schedule

          -  Able to speak and read English

          -  Willing and able to give written informed consent

        Exclusion Criteria:

          -  Obesity of known endocrine or genetic origin (e.g., untreated hypothyroidism,
             Cushing's syndrome, polycystic ovary syndrome)

          -  Serious medical condition

          -  History of malignancy within the previous 5 years, with exception of non-melanoma skin
             cancer or surgically cured cervical cancer.

          -  History of suicide attempt or serious psychiatric illness

          -  History of Major Depressive Disorder within the past 2 years

          -  In need of medications for the treatment of a psychiatric disorder (with the exception
             of short-term insomnia) within the previous 6 months prior to randomization

          -  Type I or Type II diabetes

          -  History of alcohol or drug abuse or dependence as determined by the Investigator
             within 1 year prior to randomization

          -  History of surgical or device (e.g. gastric banding) intervention for obesity

          -  History of seizures or predisposition to seizures

          -  History of hypersensitivity to sulfonamides (&quot;sulfa&quot;), bupropion, or zonisamide

          -  History of treatment with bupropion SR (Wellbutrin, Zyban) or zonisamide (Zonegran)
             within previous 12 months

          -  History of nephrolithiasis (renal calculi)

          -  Loss or gain of more than 4.0 kg within 3 months prior to randomization

          -  Women of child bearing potential not adhering to a medically acceptable form of
             contraception

          -  Pregnant or breast-feeding women or planning to become pregnant during the study
             period or within 30 days of discontinuing study drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew Acampora, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Internal Medicine Associates of Charlotte</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Caroline Apovian, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nutrition and Weight Management Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James Bergthold, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Summit Research Network (Oregon), Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joseph Cleaver, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cooper Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adnan Dahdul, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>FutureCare Studies</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ken Fujioka, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nutrition and Metabolic Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeffrey Geohas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radiant Research, Chicago</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Graves, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Welborn Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alok Gupta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pennington Biomedical Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wayne Harper, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Research Associates, LLC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jonathan Henry, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Summit Research Network (Michigan), Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Diane Krieger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Miami Research Associates</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Levy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Behavioral Medical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Raymond Plodkowski, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center for Nutrition and Metabolic Disorders, University of Nevada School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Domenica Rubino, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington Center for Weight Management and Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stan Self, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SelfCenter, PC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Diane Smith, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CSRA Partners in Health, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Timothy Smith, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mercy Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Claire Waltman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Summit Research Network (Seattle), LLC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Holly Wyatt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center for Human Nutrition/UCD</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SelfCenter, PC</name>
      <address>
        <city>Fairhope</city>
        <state>Alabama</state>
        <zip>36532</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nutrition and Metabolic Research</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Human Nutrition/UCD</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami Research Associates</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CSRA Partners in Health, Inc.</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Welborn Clinic</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pennington Biomedical Research Center</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nutrition and Weight Management Center, Boston Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FutureCare Studies</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Summit Research Network (Michigan), Inc.</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48336</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Health Research</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Nutrition and Metabolic Disorders, University of Nevada School of Medicine</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89557</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Behavioral Medical Research</name>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <zip>10305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Internal Medicine Associates of Charlotte</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28277</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Research Associates, LLC</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Summit Research Network (Oregon), Inc.</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cooper Institute</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Center for Weight Management and Research</name>
      <address>
        <city>Arlington</city>
        <state>Virginia</state>
        <zip>22201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Summit Research Network (Seattle), LLC.</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 29, 2008</study_first_submitted>
  <study_first_submitted_qc>June 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 3, 2008</study_first_posted>
  <disposition_first_submitted>November 26, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>November 27, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">November 29, 2012</disposition_first_posted>
  <last_update_submitted>November 27, 2012</last_update_submitted>
  <last_update_submitted_qc>November 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 29, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>obesity</keyword>
  <keyword>zonisamide</keyword>
  <keyword>bupropion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupropion</mesh_term>
    <mesh_term>Zonisamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

